Current Edition


Bristol Myers CEO Caforio takes pay cut as ‘human capital’ metric drags down bonus

Bristol Myers Squibb is hoping new launches will offset a wave of forthcoming patent losses for some of its biggest-selling drugs. But in the meantime, …

Continue Reading →

Johnson & Johnson CEO: Consumer health split won’t interfere with our ‘more aggressive’ approach to M&A

For anyone playing a drinking game, taking a sip each time the phrase “the new Johnson & Johnson,” was uttered during the company’s fourth-quarter earnings …

Continue Reading →

Argenx, already deep into its Vyvgart launch, charts course to become immunology ‘powerhouse’: CEO

Argenx is off to the races with the launch of its new med Vyvgart. With its first FDA-approved drug Vyvgart now rolling out, Argenx is …

Continue Reading →